Home Cart Sign in  
Chemical Structure| 547-32-0 Chemical Structure| 547-32-0

Structure of Sulfadiazine sodium
CAS No.: 547-32-0

Chemical Structure| 547-32-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sulfadiazine Sodium is one of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.

Synonyms: Sulfadiazin-natrium; Sulfadiazine sodium; Sulfadiazine(sodium)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sulfadiazine sodium

CAS No. :547-32-0
Formula : C10H9N4NaO2S
M.W : 272.26
SMILES Code : O=S(C1=CC=C(N)C=C1)([N-]C2=NC=CC=N2)=O.[Na+]
Synonyms :
Sulfadiazin-natrium; Sulfadiazine sodium; Sulfadiazine(sodium)
MDL No. :MFCD00067333
InChI Key :JLDCNMJPBBKAHH-UHFFFAOYSA-N
Pubchem ID :15899898

Safety of Sulfadiazine sodium

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H318-H411
Precautionary Statements:P280-P305+P351+P338+P310
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEp-2 cells 250 μg/ml 90 h To test the inhibitory activity of sulfadiazine and its metabolites alone or in combination with pyrimethamine on Toxoplasma gondii growth in vitro. Results showed that except for N4-acetyl-sulfadiazine, all sulfa compounds possessed anti-Toxoplasma activity. Antimicrob Agents Chemother. 1995 Mar;39(3):763-5.
Staphylococcus aureus 0.1 µmol/ml 3 h Investigated the inhibitory effect of silver sulfadiazine on Staphylococcus aureus, finding that silver ions were absorbed by bacteria while sulfadiazine was not. Antimicrob Agents Chemother. 1974 Jun;5(6):582-8.
Pseudomonas aeruginosa 0.1 µmol/ml 3 h Investigated the inhibitory effect of silver sulfadiazine on Pseudomonas aeruginosa, finding that silver ions were absorbed by bacteria while sulfadiazine was not. Antimicrob Agents Chemother. 1974 Jun;5(6):582-8.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female C57BL/6 mice Long-term chronic Toxoplasma gondii infection model Oral 100 mg/kg 30 consecutive days To evaluate the effect of sulfadiazine plus pyrimethamine therapy on behavioral and neurocognitive changes in long-term chronic Toxoplasma gondii infection. Results showed that S+P therapy reduced brain cyst load, neuroinflammation and BBB disruption, lowered systemic Th1-cytokine levels, and ameliorated behavioral and neurocognitive alterations. Front Immunol. 2022 Apr 27;13:822567
BALB/c mice T. gondii GT1 strain infection model Oral 250 μg/ml For 12 consecutive days To evaluate the therapeutic efficacy of SDZ in T. gondii-infected mice, results showed improved survival rate and alleviated metabolic perturbations in treated mice. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00312-19
KM mice Toxoplasma gondii infection model Oral 200 mg/kg Once daily for 7 days To evaluate the protective efficacy of sulfadiazine sodium alone or in combination with tylosin against Toxoplasma gondii infection, results showed that combination therapy significantly prolonged survival time and increased survival rate in infected mice Parasit Vectors. 2024 Feb 10;17(1):59

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00731367 Split-Thickness Donor Sites. Phase 3 Completed - United States, Arizona ... More >> Maricopa Medical Center Phoenix, Arizona, United States, 85008 Less <<
NCT00634166 - Terminated(FDA request as stud... More >>y could not serve as the confirmatory trial as required under Subpart H approval.) Less << - -
NCT00634166 Burns Phase 4 Terminated(FDA request as stud... More >>y could not serve as the confirmatory trial as required under Subpart H approval.) Less << - United States, Alabama ... More >> University of South Alabama Medical Center Mobile, Alabama, United States, 36617 United States, California Arrowhead Regional Medical Center Redlands, California, United States, 92373 United States, Florida Shands Burn Center - Univ. of Florida Gainesville, Florida, United States, 32610 United States, Illinois Loyola University Medical Center Maywood, Illinois, United States, 60153 The Plastic Surgery Institute - Southern Illinois Univ. School of Medicine Springfield, Illinois, United States, 62794-9653 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Maryland John's Hopkins Burn Center Baltimore, Maryland, United States, 21224 United States, Missouri University of Missouri Healthcare - Dept. of Surgery Columbia, Missouri, United States, 65212 United States, North Carolina Wake Forest University - Department of General Surgery Winston-Salem, North Carolina, United States, 27157 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.67mL

0.73mL

0.37mL

18.36mL

3.67mL

1.84mL

36.73mL

7.35mL

3.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories